The third-quarter earnings season for major drugmakers, including Pfizer, Eli Lilly, AbbVie, Merck, and Bristol Myers Squibb, is underway, with Pfizer expected to report results on Oct. 29. Pfizer has consistently exceeded earnings expectations, with a four-quarter average surprise of 69.82%, despite declining COVID product sales. Overall, the Medical sector anticipates a 3.5% year-over-year earnings increase and an 8.8% revenue growth.
Novocure's Optune Lua device has received FDA approval for treating non-small cell lung cancer, claiming to disrupt malignant cell division through electric fields. The approval follows a controversial Phase 3 trial showing a 26% reduced risk of death when combined with standard therapies, although concerns about the trial's design and results have been raised. This approval could significantly boost Novocure's revenue, which has been lagging behind expenditures.
Sanofi is in negotiations with private equity firm Clayton Dubilier & Rice to sell a 50% controlling stake in its consumer health business, Opella, potentially valued at around €15 billion ($16.4 billion). This sale would allow Sanofi to focus more on its biopharmaceutical operations, which generated over €18 billion in sales in the first half of the year. Opella, known for products like Allegra and Icy Hot, operates in 100 countries and employs over 11,000 people.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
